Published in Vaccine Weekly, April 16th, 2003
According to researchers in the Netherlands, "Previously, we described the efficacy of immunization with recombinant Semliki Forest virus (SFV) expressing the human papillomavirus 16 (HPV) oncoproteins E6 and E7 in inducing HPV-specific CTLs [cytotoxic T lymphocytes] and anti-tumor responses.
"Recently, we developed a novel recombinant SFV construct encoding a relatively stable fusion protein of HPV16 E6 and E7 under control of a translational enhancer derived from the SFV capsid protein," said T....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.